Brandes Investment Partners 13F: Cuts MCK Stake by $12M
The institutional investor reduced its holdings in McKesson Corporation by 15,878 shares during the period.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brandes Investment Partners sold 15,878 shares from its stake in McKesson Corporation ($MCK), an 8.43% decrease, according to a 13F filing with the SEC dated May 15, 2026. It reported 172,487 shares worth $130.33 million at the end of the quarter.
Since the filing, $MCK is up 0.7% after 1 week, up 2.6% after 1 month and up 32.4% to date (from the $758.92 close on May 15, 2026).
Find the original: Brandes Investment Partners 13F filings on SEC EDGAR
MCK
McKesson Corporation
Key Points
- Brandes Investment Partners cut its position in McKesson Corporation MCK by 8.4% during the period, trimming 15,878 shares to end with 172,487 shares worth roughly $130.3 million.
- The medical distribution company trades near its 52-week range as institutional filings offer a backward-looking glimpse at portfolio adjustments made by large asset managers.
- Chief Executive Officer Brian Tyler disposed of 8,463 shares on June 17, 2026, fetching an average price of $775.13 per share in a transaction valued at roughly $6.56 million.
Get $MCK trade alerts by text
We text you when insiders, Congress or big funds trade $MCK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated McKesson Corporation alert may contain errors. Disclosures
Brandes Investment Partners Adjusts Position in McKesson Corporation
Brandes Investment Partners trimmed its holdings in McKesson Corporation MCK during the period, according to a Form 13F filing submitted to the Securities and Exchange Commission. The firm cut its position by an 8.4% margin, getting rid of 15,878 shares. At the close of the reporting window, the investor held 172,487 shares with a reported value of about $130.3 million. This regulatory filing captures holdings as of May 15, 2026, and may not reflect the fund's current share count.
McKesson Stock Performance and Market Context
Shares of McKesson trade well within their 52-week boundaries, hovering around the $755.60 spot price on Saturday. The medical distribution firm carries a market valuation exceeding $103 billion. Investors continue to monitor price action as the healthcare sector experiences shifting market dynamics and institutional rebalancing across major pharmaceutical suppliers.
Insider Buying and Selling at McKesson Corporation
Chief Executive Officer Brian Tyler completed a stock sale on June 17, 2026, parting with 8,463 shares. The transaction took place at an average price of $775.13, totaling roughly $6.56 million. The disposal was handled under a pre-arranged trading plan, allowing corporate insiders to buy or sell shares according to a set schedule without violating insider trading rules.
Wall Street Analyst Views on McKesson
Several research firms have updated their outlooks for the healthcare distributor in recent months. On October 16, 2026, UBS maintained a Buy rating while lifting its price target to $1,200.00. Earlier in October, Leerink Partners kept an Outperform rating while adjusting its target to $1,070.00 on October 7, 2026. RBC Capital reiterated a Sector Perform rating with an $845.00 target on September 14, 2026. Barclays also updated its view on August 19, 2026, keeping an Overweight rating and raising its target to $1,000.00.
Inside McKesson Corporation's Operations
Headquartered in Irving, Texas, McKesson operates as a key player in the healthcare supply chain. The company distributes pharmaceuticals, medical supplies, and health information technology products to retail pharmacies, hospitals, and clinics across international markets. Founded nearly two centuries ago in 1833, the firm manages complex logistics networks that connect drug manufacturers with healthcare providers.
Looking Ahead for Shareholders
Market participants await the next quarterly financial update from the medical distributor, which is scheduled for release on November 4, 2026. Institutional investors will also review subsequent 13F disclosures to see whether Brandes Investment Partners continues to pare down its stake or alters course in future reporting cycles.
Related Filing Alerts
Source: Brandes Investment Partners's 13F filing on $MCK (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Brandes Investment Partners 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts